Calliditas Therapeutics AB (publ) (CALT)
|52 Week Range||10.82-25.64|
|1y Target Est||-|
|DCF Unlevered||CALT DCF ->|
|DCF Levered||CALT LDCF ->|
|Debt / Equity||154.56%||Buy|
Upgrades & Downgrades
Latest CALT news
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains...
22 September 2023
Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't sugg...
Why Shares of Calliditas Therapeutics Are Rising Thursday
21 September 2023
Calliditas' lead therapy is Tarpeyo, which has accelerated approval from the FDA to fight a rare autoimmune disease affecting the kidney. The company plans to release updated phase 3 trial information...
Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point
3 September 2023
Calliditas Therapeutics downgrades Tarpeyo sales guidance due to slower-than-expected sales growth and market access challenges. Potential growth drivers include full-label expansion of Tarpeyo and ad...
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
21 August 2023
Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
6 July 2023
Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translat...
Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales
12 April 2023
Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confirmed the previous positive findings from the phase ...
Calliditas to participate in upcoming investor conferences
31 March 2023
STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following investor co...
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
19 March 2023
Reata Pharmaceuticals stock is soaring on the back of a recent FDA approval for a new rare disease drug. Calliditas Therapeutics stock recently jumped higher in response to positive trial results for ...
New Strong Sell Stocks for February 27th
27 February 2023
ATUS, CALT and CRC have been added to the Zacks Rank #5 (Strong Sell) List on February 27, 2023.